DEFENCE THERAPEUTICS INC
Commented by Stefan Feulner on March 11th, 2024 | 06:30 CET
Novo Nordisk, Defence Therapeutics, Bayer - Rally after the breakout?
Biotechnology has been revived after a disappointing stock market year in 2023. In addition to the interest rate cut fantasy, which should benefit the capital-intensive and innovative sector in particular, the current wave of acquisitions should lead to further price rises. Although the broad Nasdaq Biotech Index has only risen by 3% since the beginning of the year, it is currently facing key resistance levels. If these are broken through, the momentum northwards could accelerate.
ReadCommented by André Will-Laudien on February 20th, 2024 | 07:30 CET
Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?
It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.
ReadCommented by Armin Schulz on February 12th, 2024 | 07:00 CET
MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus
Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.
ReadCommented by Fabian Lorenz on February 7th, 2024 | 07:30 CET
BASF shares on the upswing, BioNTech sees breakthrough in cancer, and Defence Therapeutics benefits from study
Can BASF shareholders look forward to better times? One analyst is certainly hopeful. He believes that the chemical industry will recover in 2024. However, the price target gives pause for thought. The development of cervical cancer is also concerning. According to a new study, the number of cases has risen sharply in recent years, and with it, HPV infections. Accordingly, more HPV vaccines are urgently needed. The market volume is expected to more than double to over USD 15 billion in just a few years. Defence Therapeutics aims to become a profiteer. The biotech company is fighting cancer with its Accum™ platform. BioNTech CEO Ugur Sahin also believes that humanity will get cancer under control, thanks in part to artificial intelligence. The Company is currently working on 30 cancer therapies. Is it a good time to invest now?
ReadCommented by Stefan Feulner on January 30th, 2024 | 07:15 CET
Bayer, Defence Therapeutics, Morphosys - Biotech sector still on the upswing
The market is currently in an exceptional phase in the biotechnology sector. Following the record year of 2023, the number of M&A transactions continues to increase in the current year. The reason is clear. Many pharmaceutical giants are under pressure due to the expiration of many patents for high-revenue drugs. On the other hand, smaller, innovative companies are trading at attractive valuation levels following the corrections of recent years. In previous transactions, the acquirers paid significantly more than the current market value.
ReadCommented by André Will-Laudien on January 15th, 2024 | 06:45 CET
Biotech: Corona is back! The doublers are lurking here: BioNTech, Evotec, Defence Therapeutics and Bayer
We had almost forgotten about Corona and the good old flu, but it is back in full swing. Governments are remaining calm and holding on to their regained liberalism. However, Spain is now resorting to drastic measures again to protect vulnerable population groups. A mask is to be compulsory again in all Spanish healthcare facilities due to the increase in respiratory diseases. Health Minister Mónica García had previously failed to convince the Spanish regions of the need to introduce compulsory masks of their own accord. In some parts of the country, hospital emergency rooms are under severe pressure due to high patient numbers. Biotech stocks are showing the first signs of recovery after the sell-off in 2023. We take a look at a few selected stocks with 100% potential.
ReadCommented by Juliane Zielonka on January 11th, 2024 | 07:15 CET
From innovative cancer therapy to menopause: How Defence Therapeutics, Bayer and NVIDIA are reshaping the medical landscape
The global prevalence of lung cancer as the second most common cancer and the challenges associated with it have led Defence Therapeutics to develop an innovative solution. Through unconventional nasal delivery, following the motto "through the nose to the lungs", the non-hormonal drug enables the precise distribution of the active ingredient. This advance could replace conventional surgical procedures for lung cancer and open up new avenues in cancer therapy. Bayer aims to generate EUR 1 billion in sales in women's health. The drug aims to alleviate the many symptoms of menopause effectively and opens up new revenue prospects for Bayer in the field of women's health. NVIDIA brings pharmaceutical research into the digital age. BioNeMo, a generative AI platform, enables research and development teams to represent drugs directly on the computer. Discover the opportunities emerging for investors now.
ReadCommented by Armin Schulz on January 3rd, 2024 | 07:10 CET
Bayer, Defence Therapeutics, Pfizer - Buckle up for the rebound
As the end of the year approaches, the savvy equity investor begins to optimize their equity portfolio for tax purposes. During this time, investors are particularly keen to review their investments and make strategic adjustments to minimize the tax burden. This approach, often referred to as "tax-loss harvesting" or "loss offsetting", involves the clever realization of losses in order to reduce capital gains tax due on profits made in the same year. This means that shares that have not performed so well over the course of the year are often sold off again in December. In the new year, the selling pressure disappears, and the shares can start their rebound. Today, we are looking at three potential candidates.
ReadCommented by Fabian Lorenz on December 28th, 2023 | 07:30 CET
Morphosys with 50% risk? BioNTech and Defence Therapeutics share with positive news
Will the Morphosys share price halve? Analysts believe this is possible, although the German biotech veteran has been one of the winners in the sector this year. Overall, biotech shares were not among the favorites of investors in 2023. Nevertheless, the billion-dollar takeover of Karuna Therapeutics by Bristol-Myers Squibb announced yesterday gives the sector hope for a better performance in 2024. Today, we are focusing on three companies of different sizes, including Morphosys and Defence Therapeutics. The biotech company with a focus on immuno-oncology is closing the year with further positive news. The FDA has given the green light for the start of trials next year, which could open up a market worth billions. BioNTech has several pieces of positive news. Here, too, the FDA has made a positive statement, and the Company has achieved a milestone victory against CureVac.
ReadCommented by André Will-Laudien on December 12th, 2023 | 13:40 CET
Game Changer in Cancer - The Biotech Gold List for 2024! MorphoSys, Defence Therapeutics, BioNTech and Bayer
The International Agency for Research on Cancer estimates the number of cancer deaths worldwide for the year 2022 to be around 10 million. However, the number of new cancer cases in the same year amounted to around 20 million, and cancer is still considered incurable. Lung cancer remains the sad frontrunner, claiming the most lives worldwide. Colorectal and stomach cancer follow at a considerable distance. However, since the original launch of the "Cancer Moonshot" in 2016, the fight against this incurable disease in the US has made some progress in the realization of therapies. Recently, there has been an increase in success stories from many biotech companies, and investors' enthusiasm is palpable once again. Where are the Biotech game changers lurking for the 2024 investment year?
Read